Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 2Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беер-Шева yubykov@gmail.com
Список исп. литературыСкрыть список 1. Авдеев С.Н., Надеждин А.В., Тетенова Е.Ю. Применение препарата Труксал у героиновых наркоманов. Рус. мед. журн. 2001; 25: 1183–5. / Avdeev S.N., Nadezhdin A.V., Tetenova E.Iu. Primenenie preparata Truksal u geroinovykh narkomanov. Rus. med. zhurn. 2001; 25: 1183–5. [in Russian] 2. Дробижев М.Ю. Труксал (Хлорпротиксен) при лечении больных в общесоматической сети. Психиатрия и психофармакотерапия. 2001; 6: 215–6. / Drobizhev M.Iu. Truksal (Khlorprotiksen) pri lechenii bol'nykh v obshchesomaticheskoi seti. Psychiatry and Psychopharmacotherapy. 2001; 6: 215–6. [in Russian] 3. Казутина Е.А. Особенности опийного абстинентного синдрома у больных гепатитом С (клиника, биохимия, лечение). Автореф. … канд. мед. наук. М., 2004. / Kazutina E.A. Osobennosti opiinogo abstinentnogo sindroma u bol'nykh gepatitom S (klinika, biokhimiia, lechenie). Avtoref. … kand. med. nauk. M., 2004. [in Russian] 4. Antkiewicz-Michaluk L. The influence of chronic treatment with antidepressant neuroleptics on the central serotonin system. Pol J Pharmacol Pharm 1986; 38 (4): 359–70. 5. Antkiewicz-Michaluk L, Rokosz-Pelc A, Vetulani J. Increase in rat cortical [3H] naloxone binding site density after chronic administration of antidepressant agents. Eur J Pharmacol 1984; 102 (1): 179–81. 6. Antkiewicz-Michaluk L, Romańska I, Michaluk J et al. Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. Psychopharmacology (Berl) 1991; 105 (2): 269–74. 7. Balldin J, Berggren U, Engel J et al. Alpha-2-adrenoceptor sensitivity in early alcohol withdrawal. Biol Psychiatry 1992; 31 (7): 712–9. 8. Balldin J, Bokström K. Treatment of alcohol abstinence symptoms with the alpha 2-agonist clonidine. Acta Psychiatr Scand Suppl 1986; 327: 131–43. 9. Bauer-Miettinen U, Horazdovsky-Nabak R. Chlorprothixene-induced central anticholinergic syndrome. Article in German. Anaesthesist 1982; 31 (2): 98–100. 10. Bokström K, Balldin J. A rating scale for assessment of alcohol withdrawal psychopathology (AWIP). Alcohol Clin Exp Res 1992; 16 (2): 241–9. 11. Boucek J. Our experience with treatment of delirium tremens. Article in Czech. Cesk Psychiatr 1982; 78 (5): 332–8. 12. Büttner W, Heuser-Grannemann E, Krizanits F et al. Significant CO2 retention in children after premedication with Dormicum and Thalamonal. Article in German. Anaesthesist 1989; 38 (6): 285–7. 13. Chacornac R, Charlot M, Duret N. General anesthesiologic conditions in the surgical treatment of intracranial aneurysms under induced hypotension with sodium nitroprusside. Article in French. Neurochirurgie 1978; 24 (3): 155–63. 14. Farber GA, Burks JW. Chlorprothixene therapy for herpes zoster neuralgia. South Med J 1974; 67 (7): 808–12. 15. Felger HL. Chlorprothixene-enforced sleep for newly admitted patients with acute mental decompensation. Dis Nerv Syst 1971; 32 (1): 46–51. 16. Gaveau T, Viars P. Combination of chlorprothixene and phenoperidine in peripheral surgery. Article in French. Anesth Analg (Paris) 1970; 27 (6): 1007–21. 17. Healey LA, Harrison M, Decker JL. Uricosuric effect of chlorprothixene. N Engl J Med 1965; 272: 526–7. 18. Hedlund PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009; 206 (3): 345–54. 19. Huerlimann F. Postoperative pain control with “Taractan”, a new thioxanthene derivative. Article in German. Praxis 1961; 50: 223–5. 20. Jones RK. Meralgia paresthetica as a cause of leg discomfort. Can Med Assoc J 1974; 111 (6): 541–2. 21. König P. Psychiatric intensive therapy after acute alkaloid withdrawal syndrome. Article in German. Infusionsther Klin Ernahr 1979; 6 (1): 56–9. 22. Kramer PW. The management of postherpetic neuralgia with chlorprothixene. Surg Neurol 1981; 15 (2): 102–4. 23. Lehmann HE, Ban TA. The effect of hypnotics on rapid eye movement (REM). Int Z Klin Pharmakol Ther Toxikol 1968; 1 (5): 424–7. 24. Masciocchi A, Marino A. Taractan in the treatment of delirium tremens. Article in Italian. Riv Sper Freniatr Med Leg Alien Ment 1962; 86: 993–1016. 25. Matsunaga F., Kubo A. Tranquilizing agents in the therapy of gastrointestinal diseases. Article in Japanese. Chiryo 1963; 45: 1614–22. 26. Meyer S, Gottschling S, Georg T et al. Gamma-hydroxybutyrate versus chlorprothixene/phenobarbital sedation in children undergoing MRI studies. Klin Padiatr 2003; 215 (2): 69–73. 27. Nathan PW. Chlorprothixene (taractan) in post-herpetic neuralgia and other severe chronic pains. Pain 1978; 5 (4): 367–71. 28. O'Byrne P, Huguenard P, Romano P et al. Neuroplegia and extracorporeal circulation. Comparison between combinations of droperidol-phenoperidine and chlorprothixene-dextromoramide in cardiac surgery. Article in French. Ann Anesthesiol Fr 1976; 17 (12): 1405–10. 29. Persillon H. Palfium-Taractan-Valium association. Ideal vigil anesthesia in ophthalmology. Article in French. J Med Lyon 1970; 51 (182): 685–702. 30. Presslich O, Schanda H, Hermann P. Inpatient withdrawal treatment of heroin dependence with neuroleptics – an approach to addicts. Article in German. Psychiatr Prax 1983; 10 (2): 60–3. 31. Przewłocki R, Lasoń W, Majeed NH et al. Antidepressants and endogenous opioid peptide systems. Neuropeptides 1985; 5 (4–6): 575–8. 32. Ravn J. Letter: Treatment of severe chronic pain. Article in Danish. Ugeskr Laeger 1976; 138 (17): 1038. 33. Reinhardt U. Modification of tumor pain by psychotropic drugs. Article in German. Z Arztl Fortbild (Jena) 1987; 81 (4): 173–6. 34. Romieu M, Orsetti A, Jaffiol C et al. Comparison of the endocrine response under 2 kinds of anesthesia: neuroleptanalgesia of the chlorprothixene-dextromoramide type and venous anesthesia of the type alfadione-fentanyl. Article in French. Ann Anesthesiol Fr 1975; 16 (9): 711–20. 35. Sainsbury MJ. The management of delirium tremens. Med J Aust 1975; 1 (1): 15–6. 36. Salo M, Laaksonen V. The maintenance of the circulation during anaesthesia in patients with phaeochromocytoma. Ann Chir Gynaecol Fenn 1972; 61 (3): 142–51. 37. Schanda H, Presslich O, Hermann P et al. In-patient withdrawal treatment of heroin addicts with neuroleptics (author’s transl). Article in German. Wien Klin Wochenschr 1982; 94 (2): 43–8. 38. Schmidt-Holtz M. Leiomyomatosis cutis with Paroxysmal pain (author’s transl). Article in German. Z Hautkr 1981; 56 (20): 1342–51. 39. Shalev A, Hermesh H, Munitz H et al. Chlorprothixene-induced hypouricemia: a biologic indicator of drug compliance. J Clin Psychiatry 1989; 50 (11): 424–7. 40. Shalev A, Hermesh H, Munitz H. The hypouricemic effect of chlorprothixene. Clin Pharmacol Ther 1987; 42 (5): 562–6. 41. Stavric B, Clayman S, Gadd RE et al. Some in vivo effects in the rat induced by chlorprothixene and potassium oxonate. Pharmacol Res Commun 1975; 7 (2): 117–24. 42. Sugai T, Kimura S, Niimura K. Effects of methixene hydrochloride on urinary tract calculi: effects as an analgesic and on spontaneous passages of stones. Article in Japanese. Hinyokika Kiyo 1968; 14 (8): 605–18. 43. Tagashira E, Hiramori T, Urano T et al. Enhancement of drug withdrawal convulsion by combinations of phenobarbital and antipsychotic agents. Jpn J Pharmacol 1981; 31 (5): 689–99. 44. Van Coller PE. Flupenthixol (fluanxol) in the treatment of psychosomatic disorders in medicine. Psychosomatics 1971; 12 (4): 256–9. 45. Viars P, Gaveau T. Reflections on the clinical use of phenoperidine (continued). Article in French. Anesth Analg (Paris) 1968; 25 (4): 373–87. 46. Volle E, Park W, Kaufmann HJ. MRI examination and monitoring of pediatric patients under sedation. Pediatr Radiol 1996; 26 (4): 280–1. 47. Waldmann H. Circadian phase alteration in the manic-depressive disease. Article in German. Fortschr Neurol Psychiatr Grenzgeb 1969; 37 (7): 383–96. 48. Weinshilboum RM, Goldstein JL, Kelley WN. Prolonged hypouricemia associated with acute chlorprothixene ingestion. Arthritis Rheum 1975; 18 (Suppl. 6): 739–41.